openPR Logo
Press release

BOC Sciences Diversifies Immune Checkpoint Inhibitors and Nonspecific Immune Stimulation for Cancer Immunotherapy

09-03-2018 12:10 PM CET | Health & Medicine

Press release from: BOC Sciences

Headquartered in Shirley, New York, the world’s reputed chemical supplier BOC Sciences announced to diversify its immune checkpoint inhibitors as well as nonspecific immune stimulation targets for scientific research targeting cancer immunotherapy (https://www.bocsci.com/tag/cancer-immunotherapy-36.html) on August 29, 2018.
Traditionally, surgery, chemotherapy and radiotherapy are the most widely chosen therapies in cancer treatment. However, in recent years, immunotherapy has attracted increasing attention among the research community. Immunotherapy agents do not directly attack the tumor cells but instead mobilize the immune system to do so. This is a major difference and its biggest advantage since it spares the limitations of traditional methods such as severe systemic toxicities and bystander effects on normal cells.
“In the past 100 years, the potential of the immune system to be mobilized to provide a reproducible benefit for patients with cancer has been gradually explored. With the approval of ipilimumab in 2011 by regulatory agencies, the field of cancer immunotherapy comes to the renaissance stage,” revealed Mr. Barron Jones, the Marketing Executive of BOC Sciences, in a statement. “So far, immunotherapy has become a more preferred choice for treating various types of cancer considering its unique potential for substantial and long-term clinical benefit.”
Previously BOC sciences has already had a quite comprehensive collection of immune checkpoint inhibitors and nonspecific immune stimulation targets, but given the importance of immunotherapy, more has been added in the hope of facilitating the research efforts of scientists in this field. Both nonspecific immune stimulation and Immune checkpoint inhibitors belong to the non-antigen-specific strategies of immunotherapy, whereas the antigen-specific strategies generally include adoptive cell transfer of autologous cancer-specific T cells and various therapeutic vaccination approaches.
Examples of immune checkpoint proteins (targets) found on T cells or cancer cells:
• IDO• TDO• PD-1• PD-L1• CTLA4• KIR• 4-1BB(also known as CD137)• OX40 (also known as CD134)• LAG3• B7‑H3(also known as CD276)• TIM3• TIGIT• BTLA• VISTA• ICOS• CD39• CD27• CD30(also known as TNFRSF8)• CD28• B7-H4(also known as B7‑S1, B7x and VCTN1)• HHLA2• Galectins• CD155
Examples of nonspecific immune stimulation proteins (targets) found on T cells or cancer cells:
• TLR• CD40• GITR• CCR• CXCR• Cytokine Receptor• STING• Cox-2• Adenosine A2a• Adenosine A2b• Others (Nonspecific immune stimulation)

About BOC Sciences
Committed to the pharmaceutical industry, BOC Sciences offers a range of high quality APIs, inhibitors, impurities, metabolites, ADCs and other chemicals as needed by researchers. To keep up with the ever-changing world, BOC Sciences also keeps an eye on the trends and efforts in seeking new treatment for major disease like cancer. In the last two decades and more, more platforms such as Virtual Screening (https://www.bocsci.com/virtual-screening.html ) and Screening Libraries (https://www.bocsci.com/screening-libraries-list-7.html ) are added in the hope of facilitating researchers’ efforts as well as accelerating drug R&D process.

BOC Sciences

45-16 Ramsey Road, Shirley, NY 11967, USA

Linna Green

account@bocsci.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release BOC Sciences Diversifies Immune Checkpoint Inhibitors and Nonspecific Immune Stimulation for Cancer Immunotherapy here

News-ID: 1215587 • Views: 346

More Releases from BOC Sciences

High-Standard Fermented Raw Materials that Satisfy the Quality Attributes of Hea …
New York, United States-Oct 12, 2022-Managing raw materials as part of the quality system will ensure that all finished healthcare products can meet quality attributes. As a comprehensive supplier of CRO/CMO/CDMO fermentation services, BOC Sciences is able to provide clients with high-standard raw materials to ensure quality attributes of final healthcare products. Some key factors that should be taken into consideration when selecting raw materials for healthcare products include sufficient
Optimal Peptides of BOC Sciences Arouse Heated Discussions at TIDES USA 2022
BOC Sciences successfully participated in TIDES USA 2022 from May 9th to 12th, at Hynes Convention Center, Boston. During the four-day exhibition, experts from BOC Sciences and global visitors are engaged in heated discussions concerning novel advances in peptide and amino acid synthesis, discovery, design, and engineering. BOC Sciences has been preparing for the world's largest gathering of pharmaceutical industry for several months. This year, it attracts a great number
A Collection of Current In-Demand COVID-19 Related Products
As the COVID-19 pandemic keeps spreading around the world with no sign of slowing down, massive research about drugs, vaccines, and other therapies is in full swing to mitigate the negative impact on human well-being. BOC Sciences offers several related products that show great benefits to the anti-epidemic activities. These include SARS-CoV-2 inhibitors and key raw materials for the production of disinfectants, test reagents, and vaccines. SARS-CoV-2 Inhibitors Vaccines are widely recognized as
BOC Sciences Provides PseudoUridines for Vaccine R&D
BOC Sciences, a vaccine raw material supplier headquartered in New York, announces providing pseudoUridine products for RNA modification to further promote the research and development of vaccines. According to BOC Sciences' latest report, its annual production of pseudoUridine (key raw material of vaccines) has ranked first in the world. Massive studies have shown that chemical modification of RNA would affect gene expression in RNA with DNA coding, assuming the actual gene

All 5 Releases


More Releases for Shirley

Clinical Rehabilitation Service Market Set for More Growth | Select Medical, Chi …
A new business intelligence report released by AMA with title "Clinical Rehabilitation Service Market" has abilities to raise as the most significant market worldwide as it has remained playing a remarkable role in establishing progressive impacts on the universal economy. The Global Clinical Rehabilitation Service Market Report offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics
Global Body and Massage Oils Market Size (2022-2030) Top Manufacturers Analysis …
For business strategists, the Body and Massage Oils Market 2022-2030 Research Report is a wonderful source of intriguing data. Covers analysis of the Body and Massage Oils market, including growth projections as well as historic and projected cost, revenue, demand, and supply statistics (as applicable). The value chain is described in-depth and your dealer is analyzed by research experts. This Body and Massage Oils analysis contains in-depth information that improves
Medical Rehabilitation Services Market Segmentation, Analysis by Recent Trends, …
The Medical Rehabilitation Services Market report upholds the future market predictions related to Medical Rehabilitation Services market size, revenue, production, Consumption, gross margin and other substantial factors. It also examines the role of the prominent Medical Rehabilitation Services market players involved in the industry including their corporate overview. While emphasizing the key driving factors for Medical Rehabilitation Services market, the report also offers a full study of the future trends
Clinical Rehabilitation Service Market Show at 5.9% CAGR to 2025 | Shirley Ryan …
Global Clinical Rehabilitation Service Market Growth Status and Outlook 2020-2025 According to this study, over the next five years the Clinical Rehabilitation Service market will register a 5.9% CAGR in terms of revenue, the global market size will reach $ 211770 million by 2025, from $ 168300 million in 2019. In particular, this report presents the global revenue market share of key companies in Clinical Rehabilitation Service business, shared in Chapter
Medical Rehabilitation Services Market 2019: Top Key Players Are Shirley Ryan Ab …
Medical Rehabilitation Services Market 2019 Report analyses the industry status, size, share, trends, growth opportunity, competition landscape and forecast to 2025. This report also provides data on patterns, improvements, target business sectors, limits and advancements. Furthermore, this research report categorizes the market by companies, region, type and end-use industry. Get Sample Copy of this Report@ https://www.researchreportsworld.com/enquiry/request-sample/13831295 Global Medical Rehabilitation Services market 2019 research provides a basic overview of the industry including
Global Rose Extract Market 2018 - JURLIQUE, Florihana, Shirley Price, Tisserand, …
Apex Market Reports, recently published a detailed market research study focused on the “Rose Extract Market” across the global, regional and country level. The report provides 360° analysis of “Rose Extract Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Rose Extract on